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The goal of this study was to determine the effect of deltamethrin, a pyrethroid insecticide, on 
CaV3.2, a human T-type voltage-sensitive calcium channel expressed in Xenopus laevis (X. 
laevis) oocytes. CaV3.2 cDNA was transcribed into cRNA; the cRNA was then injected into X. 
laevis oocytes and electrophysiologically characterized using the two-electrode voltage clamp 
technique with Ba
2+ as a charge carrier. Deltamethrin (10
-7 M) reduced peak current in a 
nonreversible manner compared to the untreated control, but had no effect on the voltage-
dependent activation and inactivation kinetics. These findings confirm that human CaV3.2 is a 
target for deltamethrin and quite possibly other pyrethroid insecticides. These studies provide 
insight into the molecular mechanisms of the effect that pyrethroids have on voltage-sensitive 
calcium channels in general.  This information will allow a more complete understanding of the 
molecular and cellular nature of pyrethroid-induced toxicity and expand our knowledge of the 
structure-activity relationships of pyrethroids with regard to their action on voltage-sensitive 
calcium channels.  
 
Abbreviations:  Cav3.2, T-type voltage-sensitive calcium channel; DMSO, dimethyl sulfoxide; 
HEPES, N-[2-hydroxyethyl]piperazine-N’[2-ethanesulfonic acid] 
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Introduction 
 
Pyrethroids  are  widely  used  insecticides 
in  both  agricultural  and  urban  environments 
because  of  their  high  insecticidal  effects,  their 
relatively  low  mammalian  toxicity,  and  their 
biodegradability  (Motomura  et  al.,  2001). 
Pyrethroids  are  synthetic  analogs  of  pyrethrins, 
which are natural esters found in the pyrethrum 
extract from the flower heads of Chrysanthemum 
cinerariaefolium.  They  have  been  used 
extensively for over forty years and comprise 25% 
of the worldwide insecticide market (Shafer et al., 
2005).  Pyrethroids  were  developed  due  to  the 
instability  that  pyrethrins  have  to  light  and  air. 
Pyrethroids have both greater stability and greater 
potency  than  their  natural  counterparts  (Casida, 
1980).  
All toxic pyrethroids are characterized as 
acute  excitatory  neurotoxicants,  which  target 
voltage-sensitive  sodium  (VSSC),  voltage-
sensitive  calcium  (VSCC)  and  voltage-sensitive 
chloride  (VSClC)  channels  in  the  rat  model 
system  (Soderlund  et  al.,  2002).  Other  potential 
targets  of  pyrethroids  have  been  identified  and 
include  glutamate,  GABA  and  acetylcholine 
receptors, as well as ATPases (Raymond-Delpech 
et al., 2005).  
Pyrethroid toxicity depends on the three-
dimensional configuration of the entire molecule, 
and its activity is highly stereospecific (Shafer et 
al.,  2005).  Based  on  their  relative  chemical 
structures,  pyrethroids  can  generally  be  divided 
into  two  categories.  CS-syndrome  pyrethroids, 
such as deltamethrin, possess an α-cyano moiety 
and  induce  a  choreoathetosis-salivation  response 
and  result  in  a  broader  range  of  toxic  events 
including  enhanced  neurotransmitter  release  and 
cardiac  contractions  (Clark,  1994;    Ghiasuddin, 
1985).  T-syndrome  pyrethroids,  which  do  not 
possess  this  moiety,  induce  a  tremor  response 
similar to the symptoms induced by DDT, known Page 2 of 9 
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as  DDT  jitters  (Narahashi,  1992).  Given  this 
dichotomy of symptoms induced by pyrethroids, 
multiple  mechanisms  of  action  for  this  class  of 
compounds  have  been  proposed  (Clark  and 
Brooks, 1989).  
In whole cell voltage-clamp experiments, 
non α-cyano containing pyrethroids usually elicit 
large  depolarizing  after-potentials  and  repetitive 
discharges, similar to the well-established voltage-
sensitive  sodium  channel  agonist,  DDT. 
Pyrethroids  that  contain  an  α-cyano  moiety 
usually  elicit  a  different  effect,  which  results  in 
conduction  block  (Lund  and  Narahashi,  1983). 
Since all toxic pyrethroids actively target voltage-
sensitive  sodium  channels  (VSSC),  additional 
target sites (i.e., VSCC and VSClC) may explain 
the  dichotomy  of  symptoms  present  with 
pyrethroid exposure (Soderlund et al., 2002).  
There  are  several  different  experimental 
approaches that can be used to analyze the mode 
of  action  of  the  pyrethroid  insecticides.  These 
methods  include  electrophysiology  experiments 
(including  voltage  and  whole-cell  patch  clamp 
techniques),  radioligand  binding  and  ion  flux 
studies  (Raymond-Delpech  et  al.,  2005). 
Electrophysiological  techniques  measure  the 
electrical  current  that  is  formed  from  the 
movement  of  ions  across  the  membrane  (Soreq 
and Seidmas, 1992). The movement of ions across 
the membrane as measured in electrical currents 
allows the researcher to measure the opening and 
closing of the channel, based on the levels of ion 
current.    Rates  of  activation,  inactivation  and 
deactivation  of  the  VSCCs  can  be  analyzed  by 
fitting  the  curves  (generated  from  the  data 
resulting  from  electrophysiological  recordings) 
with single exponential curves, which allows the 
determination of time constants (tau, τ). X. laevis 
oocytes were chosen for these studies because of 
their well established role as a model system for 
ion  channel  expression  and  their  use  in  two 
electrode voltage-clamp electrophysiology.  
Calcium  is  an  important  second 
messenger  in  many  cellular  pathways.  VSCCs 
control the flux of ions between the membranes in 
response  to  membrane  depolarizations,  thus 
regulating many intracellular processes (Williams 
et al., 1999; Catterall et al., 2005). Based on their 
biophysical  and  pharmacological  characteristics, 
there are two categories that comprise the calcium 
channel  family,  high-voltage  activated  and  low-
voltage  activated  channels.  The  high-voltage 
activated channel category includes the L-, N-, P/ 
Q-  and  R-type  channels,  while  the  low-voltage 
activated  channel  includes  the  T-type  channel 
(Williams et al., 1999). The low-voltage activated 
calcium channels are classified as the CaV3 family 
and  include  CaV3.1,  CaV3.2  and  CaV3.3,  also 
named by their corresponding α1 subunits of α1G, 
α1H  and  α1I,  respectively  (Gomora  et  al.,  2002, 
Chemin et al., 2006; Michels et al., 2002). 
Low-voltage activation and inactivation in 
a negative steady state and slow deactivation are 
characteristics  of  Cav3  channels  and  distinguish 
them  from  the  high-voltage  activated  channels 
(Catterall et al., 2005; McRory et al., 2001). T-
type  calcium  channel  currents  are  also 
distinguished  pharmacologically  by  their  high 
sensitivity  to  mibefradil,  a  calcium  channel 
antagonist that selectively blocks voltage-sensitive 
T-type current in relatively low doses (Abernethy, 
1997;  Klugbauer  et  al.,  1999).  Low-voltage 
activated channels are expressed in many different 
cell  types  where  they  shape  the  action  potential 
and  control  patterns  of  repeated  firing,  which 
leads  to  controlling  functions  such  as  cardiac 
pacemaker activity, gene expression modulation, 
cortisol  secretion,  control  of  the  mammalian 
acrosome reaction and neurotransmission (Arnoult 
et al., 1998; Cribbs, 2006; Catterall et al., 2005). 
The  inhibition  of  calcium  current  in  cells  by 
pyrethroids would result in less current, leading to 
less calcium influx into the neurons and reduced 
electrical  excitability  in  the  brain  and  rhythmic 
beating of the heart (Catterall et al., 2005).  
An  agonistic  action  of  pyrethroids  at 
VSCCs in a variety of electrophysiological studies 
has been established and these actions at VSCCs 
are  dependent  upon  the  compound  tested,  the 
channel  examined,  and  the  preparation  used 
(Soderlund  et  al.,  2002;  Narahashi  et  al.,  1987; 
Hildebrand  et  al.,  2004;  Symington  and  Clark 
2005; Symington et al., 2007). Pyrethroids block 
distinct  classes  of  VSCCs  in  a  variety  of  non-
neuronal  mammalian  systems.  In  mouse 
neuroblastoma cells (N1E-115), tetramethrin, a T-
syndrome  pyrethroid,  preferentially  blocked  T-
type calcium current by 75% but only 30% of the 
L-type current (Narahashi et al., 1987; Yoshii et 
al.,  1985).  Tetramethrin  also  blocked  a  T-type 
calcium channel current in rabbit sino-atrial node 
cells.  Electrophysiological  studies  using  Cav3.1 Page 3 of 9 
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(T-type), Cav1.2 (L-type), and Cav2.1 (P/Q-type) 
expressed  in  non-neuronal  HEK  cells  indicated 
that  allethrin,  a  T-syndrome  pyrethroid,  blocked 
all three channels (Hildebrand et al., 2004). Rat 
brain  Cav2.2  α1β-subunit,  coexpressed  with   β3 
subunit  in  X.  laevis  oocytes,  is  inhibited  by 
deltamethrin  in  a  stereospecific  concentration-
dependent manner with an approximate IC50 of 1 
nM (Symington and Clark 2005). Unfortunately, 
direct comparisons of the potency and efficacy of 
pyrethroids on these channels are unreliable at this 
time because of different experimental protocols 
and preparations used.  
Shafer and colleagues (Shafer et al., 2005; 
Shafer  and  Meyer,  2004)  have  formulated  a 
number  of  critical  needs  necessary  for  a 
meaningful  assessment  of  the  cumulative 
development  and  neurotoxicity  of  pyrethroid 
insecticides.  Among  these  needs  is  a  critical 
assessment of the action of pyrethroids on T-type 
VSCC  and  the  physiological  functions  mediated 
by  these  channels.  Early  indications  are  that  T-
type  VSCCs  are  more  sensitive  to  pyrethroids 
than  other  classes  of  VSCC.  Furthermore,  it  is 
unclear if pyrethroids elicit their actions on human 
channels  differently  than  other  mammalian 
VSCCs  since  no  human  channels  have  been 
characterized  with  respect  to  pyrethroid 
modification.  
In  this  research,  we  performed  two-
electrode  voltage  clamping  on  X.  laevis  oocytes 
expressing  the  human  T-type  calcium  channel 
(Cav3.2). It is hypothesized that deltamethrin will 
inhibit Cav3.2.  
 
 
Materials and Methods 
 
Materials 
  The  technical  grade  pyrethroid 
deltamethrin  ((S)-α-cyano-3-phenoxybenzyl 
(1R,3R)-3-(2,2-dibromovinyl)-2,2-dimethylcyclo 
propanecarboxylate) was provided by Pyrethroid 
Working  Group  (Bayer  Leverkusen,  Germany; 
DuPont  worldwide;  FMC  Philadelphia,  PA; 
Syngenta  Basel,  Switzerland;  Valent  Walnut 
Creek,  CA).  Deltamethrin  was  dissolved  in 
dimethyl  sulfoxide  (DMSO)  to  make  a  10
-2  M 
stock solution and serial diluted to the necessary 
concentrations.  The  restriction  endonucleases 
ClaI, HindII and AflII were obtained from New 
England  Biolabs  (Ipswich,  MA).  All  other 
chemicals were purchased from Sigma Chemical 
Company (St. Louis, MO).  
 
Calcium Channel Clones 
The CaV3.2 α1H construct was a generous 
gift from Dr. Edward Perez-Reyes (University of 
Virginia).  CaV3.2  cDNA  full-length  clone  was 
transformed  using  OneShot  TOP  10F 
(Invitrogen Carlsbad, CA) and plated on LB agar 
plates  (Tryptone,  Yeast  Extract,  NaCl,  Agarose) 
containing  100  µg/ml  ampicillin.  Plates  were 
incubated overnight at 37°C and the following day 
colonies  were  selected  and  placed  into  Falcon 
tubes  containing  LB  broth  (Tryptone,  Yeast 
Extract,  NaCl)  with  100  µg/ml  ampicillin  and 
incubated  overnight  at  37°C.  The  DNA  was 
extracted  from  the  overnight  cultures  using  the 
procedure  as  outlined  in  the  Quantum  Prep 
Plasmid Miniprep Kit manual (Bio-Rad Hercules, 
CA). Individual clones were verified by restriction 
mapping using the restriction endonucleases ClaI 
and HindIII.  
The  verified  CaV3.2  plasmid  was  then 
linearized using the restriction endonuclease AflII 
and was gel purified on a 0.8% TAE gel (agarose, 
TAE buffer [Tris-Cl, Glacial Acetic Acid, 0.5 M 
EDTA, pH 8.0]) using the GeneClean® Kit (Q-
Bio  Gene,  Irvine,  CA)  following  the 
manufacturer’s instructions. The concentration of 
the  linearized  plasmid  was  determined  using  a 
spectrophotometer  (NanoDrop®  ND-100, 
Wilmington,  DE)  and  the  linearized  plasmid 
resuspended to a final concentration of 1µg/µl in 
TE  Buffer  (Tris-Cl,  0.5  M  EDTA).  Purified 
plasmid was then used as a template for in vitro 
transcription  (described  in  the  mMessage 
mMachine protocol from Ambion (Austin, TX)) 
and  the  newly  transcribed  cRNA  was  recovered 
using a 0.1µg/µl lithium chloride precipitation and 
washed  with  70%  ethanol.  The  cRNA  was 
verified using a 1% agarose denaturing gel prior 
to examining the integrity of the transcript. 
 
Xenopus laevis oocytes and cRNA injections 
Xenopus  laevis  ovaries  containing  the 
oocytes  were  purchased  from  NASCO  (Fort 
Atkinson,  WI).  Oocytes  were  defollicated  in 
2mg/mL  collagenase  solution  (collagenase,  OR2 Page 4 of 9 
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buffer [82.5mM NaCl, 2mM KCl, 1mM MgCl2, 
5mM  N-(2-hydroxyethyl)piperazine-N’-(2-ethane 
sulfonic acid] (Hepes); pH 7.5 with NaOH) for 30 
minutes,  followed  by  manual  defollication  with 
forceps. Healthy stage V-VI oocytes were selected 
for  injection.  The  oocytes  were  stored  in  tissue 
culture  dishes  at  19°C  in  ND96
  (96mM  NaCl, 
2mM KCl, 1.8mM CaCl2, 1mM MgCl2, 5mM N-
(2-Hydroxyethyl)piperazine-N’-(2-ethane sulfonic 
acid) (Hepes); pH 7.5 with NaOH) supplemented 
with 1% sodium pyruvate, 1% Penicillin and 1% 
horse serum. 
  The  pipettes  for  injection  were  pulled 
with  Flaming/Brown  Micropipette  Puller  Model 
P-97  (Sutter  Instrument  Co.,  Novato,  CA).  The 
injection needles were attached to a Nanoliter2000 
(World Precision Instruments, Sarasota, FL) and 
backfilled  with  mineral  oil  to  avoid  cRNA 
contamination.  The  injection  needles  were  then 
filled  with  the  cRNA  to  be  injected  at  a 
concentration  of  0.05  mg/mL.  The  stage  V 
oocytes were injected with approximately 23nL of 
RNA and the stage VI oocytes were injected with 
approximately  46nl  of  cRNA.  The  injected 
oocytes  were  allowed  to  incubate  at  19°C  until 
electrophysiological recordings. 
 
Electrophysiology 
  CaV3.2  expression  was  examined  using 
two  electrode  voltage-clamping  following 
incubation of the oocytes. Current was recorded in 
the  two-electrode  voltage  clamp  configuration 
using  an  AxoPatch™  2B  amplifier  (Axon 
Instruments, Foster City, CA).  Electrodes (1-5 Ω) 
were  pulled  with  Flaming/Brown  Micropipette 
Puller Model P-97 (Sutter Instrument Co. Novato, 
CA)  and  backfilled  with  3M  KCl  for  this 
technique.  The  oocytes  to  be  pierced  for 
recordings were first washed with a BaCl2 buffer 
(5mM  BaCl2  dehydrate,  85mM  tetraethyl 
ammonium  chloride,  5mM  KCl,  5mM  N-(2-
hydroxyethyl)piperazine-N’-(2-ethanesulfonic 
acid) (Hepes); pH 7.5). The recordings were made 
using pClamp 9.0™ software (Axon Instruments, 
Foster City, CA). 
Mibefradil  was  used  in  initial 
electrophysiological  experiments  in  order  to 
distinguish  whether  the  calcium  channel 
expression  was  due  to  the  expression  of  the 
CaV3.2 channel or endogenous calcium channels 
within  the  X.  laevis  oocyte.  DMSO  diluted  in 
BaCl2 buffer was employed as a control.   
 
Pyrethroid Treatment  
Following  the  control  recordings,  the 
injected X. laevis oocyte was treated with 10
-7 M 
of deltamethrin, using a superfusion system. The 
injected X. laevis oocyte was perfused with BaCl2 
buffer  (5mM  BaCl2  dehydrate,  85mM  tetraethyl 
ammonium  chloride,  5mM  KCl,  5mM  N-(2-
hydroxyethyl)piperazine-N’-(2-ethanesulfonic 
acid) (Hepes); pH 7.5) for 2 minutes, as a control. 
After the 2 minutes, the oocyte was perfused with 
either  the  treatment  of  DMSO  (as  a  control)  or 
deltamethrin for 10 minutes. Following treatment, 
the oocyte was perfused again with BaCl2 buffer 
for 8 minutes.  
Electrophysiological  recordings  took 
place  following  the  10-minute  superfusion  with 
either  the  DMSO  control  or  deltamethrin. 
Following the recordings, the oocyte went through 
an  8-minute  superfusion  of  BaCl2,  in  order  to 
remove  any  residual  DMSO  or  deltamethrin 
before moving onto the next superfusion.  
In  the  washout  protocol,  superfusion  of 
the X. laevis oocyte with 10
-7 M deltamethrin was 
extended to 30 minutes and was followed by a 10 
minute wash out period. This was done in order to 
optimize the amount of time the oocyte should be 
superfused  with  BaCl2  in  between  control  and 
deltamethrin treatments.  
 
Data Analysis 
  The  data  that  was  generated  from  the 
electrophysiology  experiments  was  analyzed 
using  the  Clampfit  9.2  and  GraphPad  Prism 
software  (version  3.00  for  Windows,  GraphPad 
software,  San  Diego  CA,  USA).  Statistical 
significance  of  changes  in  all  results  was 
determined using the Student’s t-test, using P < 
0.05  as  criteria  for  evaluation.  All  statistical 
analysis was done following the methods outlined 
in the paper by Symington and Clark (2005).  
 
Results 
 
CaV3.2  expression  in  X.  laevis  oocytes 
was confirmed using the T-type VSCC antagonist, 
mibefradil. Figure 1A illustrates sample traces of 
CaV3.2  current  in  the  presence  and  absence  of Page 5 of 9 
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mibefradil  (10
-6  M).  Treatment  with  10
-6  M 
mibefradil  caused  a  2.3-fold  reduction  in  the 
relative peak current and a 1.3-fold decrease in the 
total area under the curve compared to the control. 
These results indicate that CaV3.2 expression in X. 
laevis oocytes is blocked with mibefradil, which is 
consistent  with  previous  findings  (Cribbs  et  al., 
1998).  Figure  1B  illustrates  sample  traces  of 
CaV3.2  expressed  in  X.  laevis  oocytes  in  the 
presence and absence of deltamethrin. Treatment 
with  10
-7  M  deltamethrin  caused  a  2.3-fold 
decrease  in  relative  peak  current  and  a  2.0-fold 
decrease in the area under the curve.  
 
The  irreversibility  of  deltamethrin 
antagonism is shown in Figure 2. Superfusion  
application  of  deltamethrin  (10
-7  M)  for  30 
minutes  indicates  that  deltamethrin  inhibition  of 
the relative peak current is slow (>10 min). Also, 
deltamethrin  inhibition  of  peak  current  was 
irreversible  since  relative  peak  current  values 
remained constant after the deltamethrin treatment  
was removed (time 30 - 40 min, Figure 2) in a 
washout. 
The effect that deltamethrin elicits on the 
current-voltage relationship of CaV3.2 is shown in 
Figure 3. The control current exhibited properties  
 
that  are  characteristic  of  low-voltage  activated 
calcium  channels,  including  low-threshold 
 
Figure  1.  Effects  of  mibefradil  (10
-6  M)  and 
deltamethrin (10
-7 M) on CaV3.2 expressed in X. laevis 
oocytes. A. Representative current recordings illustrating 
the  effects  of  mibefradil  (10
-6  M)  on  the  CaV3.2  under 
steady-state depolarization. Mibefradil caused a 2.3-fold 
reduction  in  peak  current  of  CaV3.2.  B.  Representative 
current recordings illustrating the effects of deltamethrin 
(10
-7 M) on the CaV3.2 under steady-state depolarization. 
10
-7 M deltamethrin caused a 1.3-fold reduction in peak 
CaV3.2  current.  Currents  were  evoked  by  steady-state 
depolarizations to -20 mV from a holding potential of -80 
mV for 250 ms. All recordings were made using 5 mM 
Ba
2+ as a charge carrier.  
 
  Figure  2.  Irreversibility  of  treatment  with 
deltamethrin (10
-7 M). Application of deltamethrin (10
-7 
M)  blocks  CaV3.2  current.  Deltamethrin  (10
-7  M)  was 
applied for the length of the solid bar above the graph 
and the washout began where indicated (30 min.). Error 
bars indicate standard deviation. 
 
 
Figure 3. Kinetic properties of the expressed CaV3.2 
channel. The current-voltage relationship of the CaV3.2 
channel  expressed  in  X.  laevis  oocytes  in  the  presence 
and absence of deltamethrin (10
-7 M). In the presence of 
deltamethrin, there was approximately 40% reduction in 
peak  current,  compared  to  the  non-treated  control. 
Currents  were  evoked  with  5  mV  step  depolarizations 
from  a  holding  potential  of  -80  mV  to  +20  mV.  All 
recordings  were  made  using  5mM  Ba
2+  as  a  charge 
carrier. Error bars indicate standard deviation.  
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activating  potentials  (Cribbs  et  al.,  1998). 
Deltamethrin-treated  oocytes  expressing  CaV3.2 
exhibited  a  similar  current-voltage  relationship, 
except that the relative peak current was reduced 
compared to non-treated control, with a maximum 
inhibitory response at approximately 40%. 
The  data  from  the  current  voltage 
relationship  was  transformed  into  conductance 
values (Cribbs et al., 1998) and then fit to the  
the  Boltzmann  equation  (Table  1)  in  order  to 
determine the midpoint potential of activation (VA 
50)  and  the  midpoint  potential  of  inactivation. 
Deltamethrin  (10
-7M)  had  a  VA  50  of  –40.9  mV     
± 0.9, which was not significantly different from 
control (–42.2 mV ± 0.6, t-test, n < 5, P > 0.05). 
Likewise,  no  significant  differences  were 
observed for the inactivation midpoint potentials 
(VI  50)  in  the  presence  and  absence  of 
deltamethrin.  Boltzmann  fit  of  the  inactivation 
data  indicates  that  deltamethrin  had  an 
inactivation midpoint potential of –63.3 mV ± 0.7 
which was not statistically different compared to 
the  control  (–62.2  mV  ±  0.4,  t-test,  n  <  5, P  > 
0.05). 
 
 
 
Kinetic analysis of the CaV3.2 currents is 
shown  in  Figure  4.  Deltamethrin  (10
-7  M) 
exhibited  effects  on  both  of  these  kinetic 
properties  of  calcium  channels.  The  rates  of 
activation,  inactivation,  and  deactivation  were 
analyzed  by  fitting  the  curves  with  single 
exponential curves. From these single exponential 
fits of the curves we were able to determine the 
time  constants  (τ).  Activation  τ  values  (Figure 
4A)  for  the  control  were  higher  at  low  test 
potentials  than  at  high  test  potentials.  In  the 
  Figure 4. Voltage dependence values for time constants 
(τ)  of  activation,  inactivation  and  deactivation  for 
CaV3.2  channel  in  the  presence  and  absence  of 
deltamethrin  (10
-7  M).  A.  Activation  τ  values  were 
calculated  from  the  exponential  fit  of  the  data  from 
baseline to peak current. Currents were evoked with a 5 
mV step depolarization from a holding potential of -80 mV 
to 0 mV. Activation τ values were plotted as a function of 
test potential. B. Inactivation τ values were calculated from 
the exponential fit of the data from the peak current to the 
baseline. An asterisk indicates a significant difference over 
the  control.  Currents  were  evoked  with  10  mV  step 
depolarization from a holding potential of -120 mV to 0 
mV.  All  recordings  were  made  using  5  mM  Ba
2+  as  a 
charge  carrier.  C.  Effects  of  deltamethrin  on  the 
deactivation of CaV3.2. CaV3.2 tail currents were elicited 
by a voltage protocol including a 10 millisecond step to     
-20 mV followed by repolarization to various potentials. 
There were no statistical differences for the activation τ 
and deactivation τ, and the statistical difference for the –60 
mV point for the inactivation τ is not enough to indicate a 
statistical  difference  between  deltamethrin  treated  and 
control. Error bars represent standard deviation.  
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presence of deltamethrin, the same characteristics 
were observed, showing no statistical differences 
when  compared  to  the  control.  Inactivation  τ 
values (Figure 4B) elicited the same pattern as the 
activation τ. However, the inactivation τ exhibited 
the only significant difference versus control for 
the -60 mV point.  Deltamethrin also had no effect 
on  the  repolarization  of  the  T-type  calcium 
channels,  exhibited  by  no  change  in  the 
deactivation τ values (Figure 4C). In the presence 
of  deltamethrin  (10
-7  M),  the  first  value  for  the 
inactivation  τ  at  -60  mV  was  the  only  kinetic 
value that illustrates any change in the kinetics of 
CaV3.2.  Deltamethrin  (10
-7  M)  had  no  effect  on 
the activation τ or inactivation τ values.  
 
 
Discussion 
 
These studies are the first reported on the 
effects of a pyrethroid insecticide on a human T-
type  VSCC.  The  early  indications  that  T-type 
VSCCs  are  more  sensitive  to  pyrethroids  than 
other  classes  of  VSCC  were  validated  in  this 
research  using  electrophysiological  techniques. 
From  these  techniques,  functional  evidence  was 
produced  to  show  that  deltamethrin  inhibits  the 
peak  current  of  CaV3.2,  but  does  not  have  an 
effect on the kinetics of CaV3.2.  
Figure  2,  showing  the  irreversibility  of 
deltamethrin binding to CaV3.2 after 30 minutes of 
superfusion,  can  be  supported  by  previous 
research done by Watkins et al. (2007). Watkins 
and  colleagues  take  into  account  various 
superfusion times (5 minutes to 1 hour) in order to 
demonstrate that the oocytes can accumulate the 
pyrethroids not only by having them bind to the 
ion  channels,  in  this  case  sodium  channels,  but 
also into the membrane and lipids of the oocytes. 
These  effects  can  be  explained  by  the  highly 
lipophilic  nature  of  the  pyrethroids  and  their 
affinity to bind to the ion channels. It is not clear 
whether the irreversibility of deltamethrin binding 
is caused by the lipophilic nature of deltamethrin 
or the inability of deltamethrin to dissociate from 
the  oocyte.  Future  studies  looking  at  different 
pyrethroid pesticides would allow a further look at 
the  irreversibility  of  binding  and  whether  there 
would be competition in binding between various 
types of pyrethroids. 
The effect of deltamethrin when compared 
to the control on CaV3.2 kinetics is illustrated in 
Figure  4.  A  defining  characteristic  of  T-type 
calcium channels is that Ba
2+ currents take longer 
to activate near threshold potentials, while strong 
depolarizations produce currents that activate and 
inactivate  quickly  (Cribbs  et  al.,  1998).  Our 
findings  differ  from  the  results  produced  by 
Hildebrand  et  al.  (2004),  who  observed  that 
allethrin treatments produced a 31% increase over 
the control  inactivation rate, for the T-type α1G 
currents. Another difference that they observed in 
their  studies  of  T-type  α1G  was  that  allethrin 
increased  their  activation  rate  slightly,  although 
not  significantly.  However,  similarities  between 
the effects of deltamethrin on T-type currents and 
allethrin on T-type currents were observed when 
looking at the deactivation τ  kinetics. Hildebrand 
et  al.  (2004)  reported  no  significant  effects  of 
allethrin on the deactivation τ on any of the three 
calcium  channels  they  observed  (α1G,  α1A  and 
α1C)  similar  to  the  action  of  deltamethrin  on 
CaV3.2 (α1H).  
A  potential  reason  for  the  observed 
differences  in  the  kinetics  of  CaV3.2  and  the 
kinetics  of  the  three  different  calcium  channels 
studied by Hildebrand et al., (2004) could be due 
to  the  differences  that  exist  between  the  two 
pesticides  used  in  the  studies.  Hildebrand  et  al. 
(2004)  treated  CaV3.1  with  allethrin,  a  T-
syndrome  pyrethroid.  A  difference  between  T-
syndrome  and  CS-syndrome  pyrethroids  is  the 
presence  of  a  cyano  moiety  (Motomura  et  al., 
2001).  Deltamethrin  is  an  example  of  a  CS-
syndrome pyrethroid and this difference between 
the  two  pesticides  studied  could  be  the  main 
reason why we saw a difference in the τ kinetics 
in  our  studies  when  compared  to  the  τ  kinetics 
determined by Hildebrand et al. (2004). 
Although  originally  isolated  from  the 
heart,  CaV3.2  is  also  expressed  in  the  testis. 
Studies done with the effect of fenvalerate on T-
type  calcium  channels  in  mouse  spermatogenic 
cells have generated similar conductance-voltage 
and steady-state Ca
2+ channel inactivation curves 
to ours (Xiao et al., 2006). However, Xiao et al. 
(2006) report a shift in both curves towards the 
hyperpolarizing  direction  of  approximately  14 
mV. Their results suggest that ion permeability in 
T-type  calcium  channels  is  changed  by Page 8 of 9 
Deltamethrin Inhibits the Human T-type Voltage-Sensitive Calcium Channel (CaV3.2) 
2008 
  8 
fenvalerate. Deltamethrin treatment of CaV3.2 did 
not elicit these same results (Table 1). We saw no 
shift  in  either  the  conductance-voltage  curve  (t-
test, P > 0.05) or the steady-state Ca
2+ inactivation 
curve (t-test, P > 0.05).  
Overall,  these  results  confirm  our  claim 
that T-type calcium channels, specifically CaV3.2, 
are a target for deltamethrin and quite possibly for 
other  pyrethroid  insecticides.  Through  these 
studies, we were able to gain some insight into the 
molecular modifications that pyrethroids have on 
VSCCs  in  general.  Further  studies  with  the  1S-
deltamethrin and other pyrethroid insecticides are 
needed  along  with  electrophysiological  studies 
with  a  non-human  T-type  calcium  channel  to 
further validate our findings that pyrethroids are 
significantly  more  potent  in  human  T-type 
calcium channels.  
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